Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DMShould bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Int J Gynecol Cancer 23(5) 833-8 6/1/2013
McCann GA, Boutsicaris CE, Preston MM, Backes FJ, Eisenhauer EL, Fowler JM, Cohn DE, Copeland LJ, Salani R, O'Malley DMNeuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.Gynecol Oncol 129(1) 135-9 4/1/2013
Rath KS, Loseth D, Muscarella P, Phillips GS, Fowler JM, O'Malley DM, Cohn DE, Copeland LJ, Eisenhauer EL, Salani ROutcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer.Gynecol Oncol 129(1) 103-6 4/1/2013
Alvarez RD, Gray HJ, Timmins PF 3rd, Gibb RK, Edelson M, Fowler JM, Havrilesky LJ, McCauley DL, Nash JD, Rahaman J, Rash JK, Rodabaugh KJ, Powell MA, Bristow RE, Brown JV, Tewari D, Cliby WA, Anastasia P, Robinson WR 3rd, Shahin MS, Cantrell LA, Cloven NG, Gold MA, Hope JM, Muntz HG, Sorosky JI, Elkas JC, Frumovitz MM, Jewell E, Spillman MA, Naumann RWWe need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies.Gynecol Oncol 129(1) 3-4 4/1/2013
Monk BJ, Huang HQ, Burger RA, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Liang SX, Wenzel LPatient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.Gynecol Oncol 128(3) 573-8 3/1/2013
Brudie LA, Backes FJ, Ahmad S, Zhu X, Finkler NJ, Bigsby GE 4th, Cohn DE, O'Malley D, Fowler JM, Holloway RWAnalysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery.Gynecol Oncol 128(2) 309-15 2/1/2013
Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM Jr, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ 2nd, Van Le L, Trimble CLIs bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173.Gynecol Oncol 128(2) 155-9 2/1/2013
Backes F, Fowler JMResponse to Dr. Carter's letter to the editor regarding "Short and long term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging".Gynecol Oncol 128(1) 148 1/1/2013
Backes FJ, Tierney BJ, Eisenhauer EL, Bahnson RR, Cohn DE, Fowler JMComplications after double-barreled wet colostomy compared to separate urinary and fecal diversion during pelvic exenteration: time to change back?Gynecol Oncol 128(1) 60-4 1/1/2013
McCann GA, Taege SK, Boutsicaris CE, Phillips GS, Eisenhauer EL, Fowler JM, O'Malley DM, Copeland LJ, Cohn DE, Salani RThe impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.Gynecol Oncol 128(1) 44-8 1/1/2013
Bittoni MA, Fisher JJ, Fowler J, Maxwell G, Paskett EDAssessment of the effects of severe obesity and lifestyle risk factors on stage of endometrial cancer.Cancer Epidemiol Biomarkers Prev 22(1) 76-81 1/1/2013
Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM Jr, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ 2nd, Van Le L, Trimble CLLymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study.J Clin Oncol 30(31) 3786-91 11/1/2012
McCann GA, Smith B, Backes FJ, Rath K, Chacko S, Salani R, Eisenhauer E, Fowler J, Cohn D, O'Malley DRecurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?Gynecol Oncol 127(2) 362-6 11/1/2012
Fader AN, Seamon LG, Escobar PF, Frasure HE, Havrilesky LA, Zanotti KM, Secord AA, Boggess JF, Cohn DE, Fowler JM, Skafianos G, Rossi E, Gehrig PAMinimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers.Gynecol Oncol 126(2) 180-5 8/1/2012
Backes FJ, Brudie LA, Farrell MR, Ahmad S, Finkler NJ, Bigsby GE, O'Malley D, Cohn DE, Holloway RW, Fowler JMShort- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging.Gynecol Oncol 125(3) 546-51 6/1/2012
Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani REffect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer.Gynecol Oncol 124(2) 221-4 2/1/2012
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler JM, Greer BE, Boente M, Birrer MJ, Liang SXIncorporation of bevacizumab in the primary treatment of ovarian cancer.N Engl J Med 365(26) 2473-83 12/29/2011
Chokshi RJ, Fowler JM, Cohn DE, Bahnson R, Lumbley J, Martin, Jr. EWA single-institution approach to total pelvic exenteration.Am Surg 77(12) 1629-39 12/1/2011
Zhang Z, Knobloch TJ, Seamon LG, Stoner GD, Cohn DE, Paskett ED, Fowler JM, Weghorst CMA black raspberry extract inhibits proliferation and regulates apoptosis in cervical cancer cells.Gynecol Oncol 123(2) 401-6 11/1/2011